Specifically, the agency is recommending intravenous voriconazole (VFEND), preferably at a dose of 6.0 mg/kg every 12 hours, combined with daily intravenous liposomal amphotericin B, preferably at a dose of 7.5 mg/kg.
The agency added that the dose of amphotericin B can be reduced to 5.0 mg/kg if physicians are concerned about the potential for nephrotoxicity, especially in older patients.
A liter of normal saline before the infusion is another way to minimize the risk of nephrotoxicity, the agency noted.
In cases where people have been exposed but remain without symptoms, the CDC is not recommending antifungal prophylaxis, but patients should be monitored closely for the onset of symptoms, with a low level of suspicion for a lumbar puncture to detect changes in the cerebrospinal fluid (CSF).
The agency is also not recommending empiric antifungal treatment for patients with symptoms but normal CSF.
The clinical recommendations may change as more information becomes available, Weber said.